|
Volumn 7, Issue 10, 2001, Pages 3215-3221
|
Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin
a a a a a a b b |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BLEOMYCIN;
DOXORUBICIN;
GADOLINIUM;
GADOLINIUM TEXAPHYRIN;
TEXAPHYRIN GADOLINIUM;
UNCLASSIFIED DRUG;
ANIMAL CELL;
ANIMAL MODEL;
ARTICLE;
BONE MARROW TOXICITY;
CANCER COMBINATION CHEMOTHERAPY;
CLONOGENIC ASSAY;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG CYTOTOXICITY;
MOUSE;
NONHUMAN;
OXIDATION REDUCTION REACTION;
PRIORITY JOURNAL;
SARCOMA;
TUMOR CELL LINE;
ANIMALS;
ANTINEOPLASTIC AGENTS;
BLEOMYCIN;
CELL SURVIVAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOXORUBICIN;
DRUG SYNERGISM;
FEMALE;
HUMANS;
MALE;
METALLOPORPHYRINS;
MICE;
MICE, INBRED BALB C;
NEOPLASM TRANSPLANTATION;
NEOPLASMS, EXPERIMENTAL;
PHOTOSENSITIZING AGENTS;
RATS;
RATS, SPRAGUE-DAWLEY;
TREATMENT OUTCOME;
TUMOR CELLS, CULTURED;
|
EID: 0034797931
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (51)
|
References (36)
|